Radioimmunotherapy of Lymphomas

  • Stefano Luminari
  • Silvia Morbelli
  • Lucia Garaboldi
  • Mahila Esmeralda Ferrari
  • Alberto Biggi
Chapter

Abstract

Radioimmunotherapy (RIT) using radionuclide labeled anti-CD20 monoclonal antibodies allows for the delivery of the radionuclides directly to the surface of targeted B-cell non-Hodgkin’s lymphoma (NHL) achieving additional cytotoxic effect.

Actually the only RIT agent is 90Y-ibritumomab tiuxetan registered and commercialized as Zevalin® in the USA since February 2002 and in European Union since 2004.

In the first part, the main characteristics of the radiopharmaceutical are described including the different steps of RIT, i.e., radiolabeling and quality control procedure, the preparation of the patients for the treatment, the preparation and administration of the individual dose, and the main contraindications, risks, and collateral effects. The entire procedure reported in this chapter follows the Annex I summary of product characteristics.

In the second part dedicated to radiation protection issue, the current modalities of the treatment are reported in order to obtain the best clinical results and at the same time to respect the radiation protection recommendations, considering the patients, their relatives, and the nuclear medicine staff.

In the third part on clinical experience with Zevalin®, the most important clinical results are discussed. These studies highlight the safety and efficacy of the treatment especially in relapsed/refractory low-grade follicular lymphoma but also in other CD20-positive lymphomas. Despite these evidences, 90Y-ibritumomab tiuxetan during the time missed its high initial interest for hematologists, and at present its use became limited for various reasons. These treatments in different countries require protected dedicated rooms not always available in all hospitals; the use of this radioisotope therapy includes several complex multidisciplinary steps, and some alternative nonradioactive options to 90Y-ibritumomab tiuxetan have demonstrated several comparable advantages in terms of feasibility and efficacy. However this targeted therapy still remains an important example of the successful therapeutic use of radiolabeled antibodies in the clinical routine of hematology.

Keywords

90Y-Zevalin Radioimmunotherapy Radiolabeling Radiation protection 

References

  1. 1.
    Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S. A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol. 2016;97:275–90.  https://doi.org/10.1016/j.critrevonc.2015.09.001.CrossRefPubMedGoogle Scholar
  2. 2.
    Alcindor T, Witzig TE. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma. Curr Treat Options in Oncol. 2002;3(4):275–82.CrossRefGoogle Scholar
  3. 3.
    Knox SJ, Goris ML, Trisler K, et al. Yttrium- 90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–70.PubMedGoogle Scholar
  4. 4.
    Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–803.CrossRefPubMedGoogle Scholar
  5. 5.
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–28.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Delacroix D, Guerre JP, Leblanc P, Hickman C. Radionuclide and radiation protection data handbook 2002 (2nd edition). Radiat Prot Dosim. 2002;98:1–168.CrossRefGoogle Scholar
  9. 9.
    Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin’s lymphoma. Int J Oncol. 1999;15:1017–25.PubMedGoogle Scholar
  10. 10.
    Siegel JA, Zimmerman BE, Kodimer K, Dell MA, Simon WE. A single dose calibrator dial setting accurately measures 90Y-ibritumomab tiuxetan activity. J Nucl Med. 2003;44:317.Google Scholar
  11. 11.
    Borghaei H, Schilder RJ. Safety and efficacy of radio immunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004;34:4–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Juweid ME. Radio immunotherapy of B-cell non-Hodgkin’s lymphoma; from clinical trial to clinical practice. J Nucl Med. 2002;43:1507–29.PubMedGoogle Scholar
  13. 13.
    Bischof Delaloye A. The role of nuclear medicine in tre treatment of non-Hodgkin’s lymphoma (NHL). Leuk Lymphoma. 2003;44(Supplement 4):S29–36.CrossRefPubMedGoogle Scholar
  14. 14.
    Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkin lymphoma: radiation protection, isotope comparisons and quality of life issue. Cancer Treat Rev. 2004;30:165–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. Administration guidelines for radio immunotherapy of non-Hodgkin’s lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43(2):267–72.PubMedGoogle Scholar
  16. 16.
    Cremonesi M, Ferrari M, Paganelli G, Rossi A, Chinol M, Bartolomei M, Prisco G, Tosi G. Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety. Eur J Nucl Med Mol Imaging. 2006;33(11):1321–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Tennvall J, Fischer M, Delaloye AB, Bombardieri E, Bodei L, Giammarile F, Lassmann M, Oyen W, Brans B. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol. 2007;139(4):590–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44(3):465–74.PubMedGoogle Scholar
  20. 20.
    Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med. 2007;48(11):1871–9. Erratum in: J Nucl Med. 2007;48(12):2027CrossRefPubMedGoogle Scholar
  21. 21.
    Meredith RF. Logistics of therapy with the ibritumomab tiuxetan regimen. Int J Radiat Oncol Biol Phys. 2006;66(2 Supplement):S35–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Kaminsky MS, Ester J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin’s lymphoma: update results and long term follow-up of the University of Michigan experience. Blood. 2000;96:1259–66.Google Scholar
  23. 23.
    Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine 131I tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1361–23.CrossRefGoogle Scholar
  24. 24.
    Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with Yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47(4):629–36.CrossRefPubMedGoogle Scholar
  26. 26.
    Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–64.CrossRefPubMedGoogle Scholar
  27. 27.
    Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013;31:1977–83.CrossRefPubMedGoogle Scholar
  28. 28.
    ClinicalTrials.gov. NCT00006721 S0016 - Combination chemotherapy with monoclonal antibody therapy in treating patients with newly diagnosed non-Hodgkin’s lymphoma.
  29. 29.
    Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet Oncol. 2011;377:42–51.CrossRefGoogle Scholar
  30. 30.
    ClinicalTrial.gov. NCT00662948 Geltamo/Pethema Open study in Phase II to evaluate efficacy of initial R-CHOP combination in follicular lymphoma no treated previously. Consolidation with one dose of 90Y ibritumomab Tiuxetan (Zevalin) versus maintenance treatment with Rituximab.
  31. 31.
    Fowler NH, Neelapu SS, Fanale MA, et al. Phase II study with R-FND followed by 90-Y ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Blood. 2011;118:99.CrossRefGoogle Scholar
  32. 32.
    FIL-FLAZ12 trial EudraCT Number 2012-000251-14 A phase III multicenter, randomized study comparing consolidation with (90)Yttrium-labeled Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy vs autologous stem cells transplantation (ASCT) in patients with relapsed/refractory follicular lymphoma (FL) aged 18–65 years.Google Scholar
  33. 33.
    FIL-FOLL12 trial EudractCT Number 2012-003170-60 Randomized, multicentre, phase III, response-adapted trial to define maintenance after standard treatment in advanced Follicular Lymphoma.Google Scholar
  34. 34.
    Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, Hess G, Stein H, Kalmus J, Marcus R. Effiacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Hamlin PA, Rodriguez MA, Noy A, et al. Final results of a phase II study of sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Blood. 2010;116(21):1793.Google Scholar
  36. 36.
    Stefoni V, Casadei B, Bottelli C, et al. Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. Blood Cancer J. 2016;6(5):e425.  https://doi.org/10.1038/bcj.2016.29.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    ClinicalTrials.gov. NCT00322218 – Study comparing the Zevalin regimen with no further treatment in DLBC patients who are in complete remission after R-CHOP.
  38. 38.
    Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90–ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:5213–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Zelenetz AD, Noy A, Pandit-Taskar N, Scordo M, Rijo I, Zhou Y, O’Donoghue JA, Divgi C. Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol. 2006;24(18 suppl):7560.Google Scholar
  40. 40.
    Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advan R, Hong F, Horning SJ. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90–ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30:3119–26.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Stefano Luminari
    • 1
  • Silvia Morbelli
    • 2
  • Lucia Garaboldi
    • 2
  • Mahila Esmeralda Ferrari
    • 3
  • Alberto Biggi
    • 4
  1. 1.Haematology DepartmentArcispedale Santa Maria Nuova, IRCCS and Univerità di Modena e Reggio EmiliaReggio EmiliaItaly
  2. 2.Nuclear Medicine DepartmentIRCCS San Martino – ISTGenovaItaly
  3. 3.Medical Physics UnitEuropean Institute of OncologyMilanoItaly
  4. 4.Nuclear Medicine DepartmentSanta Croce e Carle HospitalCuneoItaly

Personalised recommendations